CC
LGND icon

Centiva Capital’s Ligand Pharmaceuticals LGND Stock Holding History

Centiva Capital’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,863
Closed -$211K – 1823
2023
Q1 		$211K Buy
+2,863
New +$204K 0.01% 1217

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $838M AUM 14.24% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Centiva Capital's LGND Position: Q2 2023 in Review

Centiva Capital sold out of Ligand Pharmaceuticals (LGND) in Q2 2023, closing a stake of 2,863 shares — an estimated $211K sold.

Centiva Capital first reported a position in LGND in Q1 2023 and held it in 1 quarter. The position peaked at $211K in Q1 2023. 204 funds tracked by Wall St. Rank hold LGND as of Q2 2023.

  • Centiva Capital reported no remaining Ligand Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Centiva Capital sold 2,863 Ligand Pharmaceuticals shares in Q2 2023, an estimated $211K.
  • Centiva Capital first reported a position in Ligand Pharmaceuticals in Q1 2023 and held it in 1 quarter.
  • Centiva Capital's Ligand Pharmaceuticals position peaked at $211K in Q1 2023.
  • 204 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2023.

Based on Centiva Capital's 13F filing for Q2 2023, filed 14 Aug 2023.